Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Gossamer Bio, Inc. following a significant stock price drop after a failed clinical trial [1][3]. Group 1: Company Overview - Gossamer Bio, Inc. is a publicly traded company on NASDAQ under the ticker GOSS [1]. - The company recently announced the failure of its Phase 3 PROSERA trial for seralutinib, which was aimed at treating pulmonary arterial hypertension [3]. Group 2: Stock Performance - Following the announcement of the trial failure, Gossamer's stock price plummeted by $1.71 per share, representing a decline of 80.14%, closing at $0.423 per share on February 23, 2026 [3]. Group 3: Legal Investigation - Pomerantz LLP is conducting an investigation on behalf of Gossamer investors to determine if there were any fraudulent activities or misconduct by the company's officers and directors [1].

Core Viewpoint - A class action lawsuit has been filed against Atara Biotherapeutics, Inc. for securities fraud, with a class period from May 20, 2024, to January 9, 2026, and investors are encouraged to participate as lead plaintiffs [1][5]. Group 1: Lawsuit Details - The lawsuit alleges that Atara made false and misleading statements regarding manufacturing issues and regulatory prospects related to the tabelecleucel Biologics License Application (BLA), which could negatively impact the company's business and financial condition [5]. - Investors who purchased Atara securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation, and the deadline to move the Court for this role is May 22, 2026 [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field, including being ranked No. 1 for the number of securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, with over $438 million secured in 2019 alone [4].

Core Viewpoint - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Thryv Holdings, Inc. due to significant losses following the company's disappointing financial results [1][3][4] Group 1: Investigation Details - The investigation focuses on whether Thryv Holdings' executive officers may have violated federal securities laws, leading to investor losses [1][4] - Thryv Holdings reported a net loss for Q4 2025 and earnings per share that fell significantly below analyst expectations, despite modest year-over-year revenue growth [3] - Following the financial results announcement on February 26, 2026, Thryv Holdings' stock price declined by 46% [3] Group 2: Company Background - Johnson Fistel, PLLP is a nationally recognized shareholder-rights law firm with multiple offices across the United States, representing both individual and institutional investors [5] - The firm has been recognized as a top plaintiffs' securities law firm, having recovered approximately $90.725 million for clients in previous cases [6]

Core Viewpoint - A class action lawsuit has been filed against Aquestive Therapeutics, Inc. for alleged securities fraud and unlawful business practices, with investors encouraged to join the lawsuit by a specified deadline [2]. Group 1: Lawsuit Details - The class action lawsuit concerns whether Aquestive and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors have until May 4, 2026, to request appointment as Lead Plaintiff if they purchased or acquired Aquestive securities during the Class Period [2]. Group 2: Company Performance and Regulatory Issues - On January 9, 2026, Aquestive received a letter from the U.S. FDA identifying deficiencies that delayed discussions on labeling for Anaphylm (Dibutepinephrine) sublingual film, which had a New Drug Application submitted [4]. - Following the FDA's letter, Aquestive's stock price fell by $2.30 per share, or 37.04%, closing at $3.91 per share on January 9, 2026 [5].

Core Viewpoint - A class action lawsuit has been filed against Richtech Robotics Inc. for alleged securities fraud and unlawful business practices [2]. Group 1: Lawsuit Details - The lawsuit involves claims that Richtech and certain officers and/or directors engaged in securities fraud [2]. - Investors have until April 3, 2026, to request to be appointed as Lead Plaintiff if they purchased Richtech securities during the Class Period [2]. Group 2: Allegations and Impact - A short report by Hunterbrook Media accused Richtech of misrepresenting its relationship with Microsoft's AI Co-Innovation Labs, claiming it was a standard customer program rather than a close collaboration [4]. - Following the allegations, Richtech's stock price dropped by $1.06 per share, or 20.87%, closing at $4.02 per share on January 29, 2026 [5].

Core Viewpoint - The Gartner class action lawsuit alleges that the company and certain executives made misleading statements regarding contract value growth and consulting segment revenue, leading to significant stock price declines following disappointing earnings reports [4][5][6]. Group 1: Allegations and Financial Impact - The lawsuit claims that Gartner created a false impression of reliable information regarding its contract value growth potential and consulting revenue outlook while downplaying risks from seasonality and macroeconomic factors [4]. - On August 5, 2025, Gartner reported a decline in overall contract value growth from 7% to 5% and ex-federal contract value growth from 8% to 6%, resulting in a stock price drop of over 27% [5]. - On February 3, 2026, Gartner announced a further decline in contract value growth by an additional 2%, disclosing a significant shortfall in its consulting segment performance, which led to a nearly 21% drop in stock price [6]. Group 2: Legal Process and Representation - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Gartner common stock during the class period to seek appointment as lead plaintiff in the class action lawsuit [7]. - The lead plaintiff is typically the investor with the greatest financial interest in the case and acts on behalf of all class members, with the ability to select a law firm for litigation [7]. Group 3: Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone, marking its fourth 1 ranking in the past five years [8]. - The firm has recovered a total of $8.4 billion for investors over the last five years, significantly more than any other law firm [8].

NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Atara Biotherapeutics, Inc. (“Atara” or the “Company”) (NASDAQ: ATRA) and certain officers.   The class action, filed in the United States District Court for the Central District of California, and docketed under 26-cv-03083, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Atara securities between May 20, 2024 and Ja ...

Core Viewpoint - A class action lawsuit has been filed against Ramaco Resources, Inc. concerning allegations of securities fraud and unlawful business practices [2][4]. Group 1: Lawsuit Details - The lawsuit involves claims that Ramaco and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors have until March 31, 2026, to request to be appointed as Lead Plaintiff if they purchased or acquired Ramaco securities during the Class Period [2]. Group 2: Allegations and Impact - Wolfpack Research published a report on October 23, 2025, alleging that Ramaco's Brook Mine is a "hoax" and that no actual mining activity occurred after its July groundbreaking [4]. - Following the report, Ramaco Resources' stock price fell by $3.81 per share, or 9.57%, closing at $36.01 per share on October 23, 2025 [4].

Core Viewpoint - Franklin BSP Realty Trust, Inc. (FBRT) is facing a securities fraud lawsuit due to alleged misrepresentation of dividend coverage, leading to significant losses for investors [1][2]. Group 1: Lawsuit Details - The lawsuit names Michael Comparato, the President and newly appointed CEO of FBRT, as a defendant, indicating his involvement in the alleged misleading statements during the class period from November 5, 2024, to February 11, 2026 [1][4]. - FBRT's shares dropped by $1.44, or 14.18%, closing at $8.71 on February 12, 2026, following a dividend cut from $0.355 to $0.20 per share [2]. - The lead plaintiff deadline for the class action is set for April 27, 2026 [5]. Group 2: Comparato's Role and Statements - As President, Comparato was involved in the daily management of FBRT's commercial real estate lending operations and had access to confidential information regarding the company's business and dividend sustainability [2][3]. - Comparato previously stated that FBRT had "more tailwinds than headwinds" and expressed optimism about "the path to dividend coverage" during the Q3 2025 earnings call [2]. - He made claims about the NewPoint acquisition positioning FBRT as a leading middle-market lender, expressing confidence just months before the dividend cut [3]. Group 3: Allegations of Misleading Information - The lawsuit alleges that Comparato participated in disseminating misleading statements while in a senior leadership role, which raises questions about the accuracy of corporate disclosures [3][4]. - On February 11, 2026, Comparato acknowledged delays in resolving and selling real estate, admitting that the company had been "over-distributing capital to investors" [3]. - His elevation to CEO on February 10, 2026, just before the dividend cut announcement, has raised concerns regarding the timing of this leadership transition [4].

Core Viewpoint - Driven Brands Holdings Inc. is facing a securities fraud lawsuit due to alleged misstatements in financial disclosures, leading to significant losses for investors [1][2]. Financial Restatement - Driven Brands disclosed on February 25, 2026, that nearly three years of financial statements required restatement due to material errors across ten categories, resulting in a nearly 40% drop in share price, losing $6.62 per share [2]. - The fiscal year 2024 10-K reported $2.34 billion in annual net revenue, claiming a 2% year-over-year increase, which is now subject to restatement [4]. Executive Accountability - Michael F. Diamond, the Chief Financial Officer, is named as an individual defendant in the class action, having assumed the role on August 9, 2024, during a critical period for the company [2][3]. - Diamond co-signed financial filings alongside the CEO, indicating direct responsibility for the accuracy of these disclosures [3][4]. - Following the resignation of the Chief Accounting Officer in January 2025, Diamond took on the additional role of interim principal accounting officer, placing him at the center of financial reporting and accounting controls [3]. Certifications and Liabilities - As CFO, Diamond signed Sarbanes-Oxley certifications attesting to the accuracy of the financial statements, which are now claimed to be materially false due to identified errors [5]. - The lawsuit asserts that Diamond had the authority to control the content of SEC filings and had access to material non-public information regarding the company's financial state [6]. Legal Context - The action includes claims under Section 20(a) of the Exchange Act, which holds controlling persons liable for primary violations of securities laws, implicating Diamond due to his senior position and involvement in public filings [6][7].